Fairbrass KM, et al. - Researchers sought to explore the impact of psychological co-morbidity on inflammatory bowel disease (IBD) in a longitudinal follow-up study. At baseline, complete demographic, symptom, and psychological co-morbidity data (anxiety, depression, and somatisation scores) were obtained from adults with IBD who were in biochemical remission (faecal calprotectin < 250 µg/g). Objective markers of disease activity, including glucocorticosteroid prescription or flare of disease activity, escalation of therapy, hospitalization or intestinal resection, have been reviewed ≥ 2 years of follow-up. Among 218 candidates, 48 had one, 13 two and nine three psychological co-morbidities at baseline. Individuals with IBD in biochemical remission had a worse disease course at baseline, with increasing psychological co-morbidity.